The World Market for Cancer Therapeutics: Forecasts to 2020 (Monoclonal Antibodies, TKIs, Vaccines, Cytokines, Gene Therapy, Chemotherapy, Others), Phase I- III Pipeline Analysis, Markets by Segment

   Single User - $3,000
   Site License (one location, 10 users) - $4,500
   Corporate License - $6,000

Published Nov 12, 2015 | 320 Pages | Pub ID: KLI5752001

Despite the advances in cancer treatment, cancer continues to affect about 4 million people annually, generating a significant loss of life, financial burden and overall strain on the health industry. Traditional therapies have failed to provide adequate treatment for these patients, signifying a need for an alternative treatment plan. Compassionate use has been granted for several therapies in the past and this trend is likely to continue. This report, The World Market for Cancer Therapeutics weaves these trends together into a detailed analysis of the market for treatments for cancer with a special emphasis on novel treatments. Market information in the report includes:
  • Cancer Market Drivers and Barriers
  • Market Estimates and Forecasts for Novel Therapies and Traditional Treatments
  • Specific Product Revenues and Market Share
  • Market Analysis by Product (Monoclonal Antibodies, Tyrosine Kinase, Inhibitors, Cancer Vaccines, Cytokines, Gene Therapy, Traditional Chemotherapy),
  • Market Size and Estimate by Cancer Type (Lung, Breast, Prostate, Stomach, Liver, Cervical, Bladder, Lymphoma, Esophageal, Colon, Brain, Head&Neck, Others), by Classification (Novel, Traditional),
  • Market Analysis by Development Stage (Phase I, Phase II, Phase III)
  • Corporate Profiles
  • Analyst Conclusions
Worldwide between 35 and 40 million people are living with cancer and nearly 8 million people lose the battle annually. The most common cancers affecting the world population include lung, breast, colon/rectum, stomach, liver, prostate, cervical, esophageal, and bladder. Cancer deaths occur in about 50% of people who develop cancer in developed countries; this is in contrast to 80% death rate in cancer patients in underdeveloped countries.

The mainstay of systemic therapy for solid and hematological malignancies in the 20th century was chemotherapy. This approach has drawbacks including toxicity to normal tissue, drug resistance and lack of efficacy. The demand for more effective and tolerable treatments has led to the development of novel therapeutic agents that specifically target the malignant cells.

The report includes statistical information for cancers by type worldwide. Specifically, cancers where there are current products available or are in development and/or have significant incidence/mortality rates are profiled. The market segments provide an overview of disease epidemiology, leading product sales, market estimates and forecasts, and competitive summary of leading providers. The report also includes several discussions on novel therapies in development and their impact on the market. Throughout the report, several market indicators, trends and barriers are discussed.

Information for this report was gathered using both primary and secondary research including comprehensive research of secondary sources such as company reports and literature; government documents and databases; research journals and reports; and general medical and business journals.

Secondary research was used to determine market size for cancer types by product sales. In instances where multiple cancers are treated with one product, a formula was used to determine distribution of sales. This included incidence and mortality rates of each cancer, typical treatment regimen, cost of individual therapy and other factors. Billing databases and pricing charts were the primary sources of information, followed by interviews to verify initial findings.

Primary research methods included telephone interviews and email correspondence with company representatives, researchers, government representatives, and physicians. These interviews were conducted with the purpose of capturing the perspectives from industry participants on the market opportunity and current trends. This was the basis of formulating forecast models and for confirming early findings related to market potential.

Companies Profiled Include:
  • AbbVie
  • Acerta Pharma
  • Adaptimmune
  • Advantagene
  • Altor BioScience
  • Amge
  • Apceth GmbH & Co. KG
  • Array BioPharma
  • Astex Pharmaceuticals
  • AstraZeneca plc
  • Bayer
  • Bellicum Pharmaceuticals, Inc.
  • BioCancell Ltd.
  • Bluebird Bio
  • Boehringer Ingelheim
  • Boston Biomedical
  • Bristol-Myers Squibb Company
  • Caladrius (NeoStem)
  • Celgene
  • Celldex Therapeutics
  • Celsion Corporation
  • Clovis Oncology
  • Cold Genesys, Inc
  • Daiichi Sankyo
  • Eisai
  • Eli Lilly & Company
  • EMD Serono
  • Galena Biopharma
  • Gamida Cell
  • Genprex, Inc.
  • Gilead Sciences
  • Immunomedics
  • Incyte
  • Inovio
  • Johnson & Johnson
  • Juno Therapeutics
  • Karyopharm Therapeutics
  • MaxiVAX 3
  • MedImmune
  • Merck & Company
  • Millennium (Takeda Oncology)
  • Momotaro-Gene, Inc.
  • MultiVir, Inc.
  • Northwest Biotherapeutics
  • Novartis
  • Oncolytics Biotech
  • OncoMed
  • OncoSec Medical, Inc.
  • Pfizer, Inc.
  • Roche
  • Sanofi
  • Seattle Genetics
  • Sevion Therapeutics
  • Takara Bio
  • Tocagen
  • VBL Therapeutics
  • ZIOPHARM Oncology, Inc.
In this report,  {{key}} appears {{searchResults.reportMatchCounts[value]}} times
We were unable to search inside this report.
No results matched your search criteria.

Search for an exact word or phrase by placing the word or phrase in quotation marks ("market trend"). Search for different versions or tenses of a word by placing an asterisk at the end of the word (pharma*).

Please note that your term must be at least three characters long and numbers will be blocked by the # sign.